Month: January 2025

Company announcement no. 1 – 2513 January 2025 Major shareholder announcement due to closing of ITC Logistic GmbH Pursuant to Section 31 of the Danish Capital Markets Act, it is hereby announced that NTG Nordic Transport Group A/S (“NTG”) as of 10 January 2025 owns a total of 954,723 treasury shares of nominally DKK 20 (in total nominally DKK 19,094,460), hereby reducing its holding of treasury shares to less than 5% of the total share capital of NTG. The decrease in treasury shares is a result of transfer of treasury shares to the seller of ITC Logistic GmbH as payment for 20% of the purchase price. Additional information For additional information, please contact:Investor relations and press:Sebastian Rosborg, Head of Investor Relations                                     +45 42 12 80 99 Sebastian.rosborg@ntg.com ir@ntg.com   ...

ORION CORPORATIONSTOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE13 JANUARY 2025 at 9.50 EET                   79,345 Orion Corporation A shares converted into B shares In accordance with Section 3 of the Articles of Association of Orion Corporation, 79,345 A shares have been converted into 79,345 B shares. The conversion has been entered into the Trade Register on 13 January 2025. The total number of shares in Orion Corporation is 141,134,278 which, after the conversion, consists of 32,752,263 A shares and 108,382,015 B shares. The number of votes of the company’s shares is after the conversion 763,427,275. Orion CorporationRené LindellCFO     Olli HuotariSVP, Corporate Functions                                                Contact person:Tuukka Hirvonen, Investor Relations, tel....

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – January 13, 2025Idorsia Ltd (SIX: IDIA) today announced that – in the coming days – the company intends to publish an invitation to a bondholder meeting for holders of its outstanding convertible bond (ISIN: CH0426820350) (the Bonds or CB 2025) with a nominal value of CHF 200 million and a conversion price of CHF 6.00 per Idorsia share, maturing on January 17, 2025. At the meeting, the company will propose changing the current terms of the Bonds to avoid short-term liquidity constraints in connection with the redemption of the Bonds. On November 27, 2024, the company announced that it had entered exclusive negotiations with an undisclosed party for global rights to aprocitentan. In addition, the company announced plans to streamline its business to reduce costs and restructure...

Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myelomaApproval based on positive pivotal ICARIA-MM phase 3 study using the China-based IsaFiRsT real-world study as bridging data, which demonstrated Sarclisa and the standard treatment Pd, improved responses and long-term outcomes compared to Pd alone in R/R MM patients Sarclisa-Pd is currently recommended by the Chinese Society of Clinical Oncology (CCSCO) and Chinese Anti-Cancer Association (CACA) treatment guidelines for this patient population Paris, January 13, 2025. The National Medical Products Administration (NMPA) in China has approved Sarclisa, an anti-CD38 medicine, in combination with pomalidomide and dexamethasone (Pd) for the treatment of adult patients with multiple myeloma (MM) who have received at least...

Klinge Biopharma GmbH (Klinge) holds the exclusive global commercialization rights for FYB203, Formycon’s biosimilar candidate to Eylea®1 Agreement builds on the proven and successful collaboration of commercialization of FYB201, Formycon’s biosimilar to Lucentis®2 (ranibizumab) in Europe The partnership broadens Teva’s biosimilars portfolio, in line with its Pivot to Growth strategyTEL AVIV, Israel, Jan. 13, 2025 (GLOBE NEWSWIRE) — Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) today announced that it has entered into a strategic collaboration with Klinge Biopharma GmbH (Klinge) and Formycon AG (FSE: FYB) for the semi-exclusive commercialization of FYB203, Formycon’s biosimilar candidate to Eylea® (aflibercept) in Europe, excluding...

Reported $2.2 billion in preliminary* full-year 2024 global product net sales, inclusive of $737 million in fourth quarter sales Pre-filled syringe FDA PDUFA on track for April 2025 to support reaching patients earlier in treatment paradigm 10 ongoing registrational studies in 2025 across efgartigimod and empasiprubart enable next wave of indications Empasiprubart to be evaluated in two head-to-head registrational studies against IVIg to position C2 inhibitor for broad, early-line use in MMN and CIDP Transition to sustainable profitability in 2025 enables continued investment in innovation January 13, 2025, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today reported preliminary financial...

DEME SECURES CONTRACT FOR FOUNDATION AND OFFSHORE SUBSTATION INSTALLATION AT FENGMIAO 1 OFFSHORE WIND FARM IN TAIWAN DEME, through its Taiwanese joint venture CDWE, has been awarded a substantial contract by Copenhagen Infrastructure Partners for the transport and installation of foundations and the offshore substation for the Fengmiao 1 offshore wind farm in Taiwan.AttachmentP2025 DEME Fengmiao 20250113 ENG

Basel, January 13, 2025 – Novartis is pleased with the decision by the US Court of Appeals for the Federal Circuit (CAFC) that affirms the validity of the Entresto® (sacubitril/valsartan) combination patent. We will work to appropriately enforce the combination patent through its pediatric exclusivity period expiring in July 2025. We will also continue to defend and protect all our important intellectual property and regulatory rights relating to Entresto. There are currently no generic versions of Entresto available in the US. DisclaimerThis press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,”...